You are here

Publications

Found 981 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2022
Smith CM, Baker RE, Proulx MK, Mishra BB, Long JE, Park SWoong, Lee H-N, Kiritsy MC, Bellerose MM, Olive AJ et al..  2022.  Host-pathogen genetic interactions underlie tuberculosis susceptibility in genetically diverse mice.. Elife. 11
Smith CM, Baker RE, Proulx MK, Mishra BB, Long JE, Park SWoong, Lee H-N, Kiritsy MC, Bellerose MM, Olive AJ et al..  2022.  Host-pathogen genetic interactions underlie tuberculosis susceptibility in genetically diverse mice.. Elife. 11
Smith CM, Baker RE, Proulx MK, Mishra BB, Long JE, Park SWoong, Lee H-N, Kiritsy MC, Bellerose MM, Olive AJ et al..  2022.  Host-pathogen genetic interactions underlie tuberculosis susceptibility in genetically diverse mice.. Elife. 11
Gold B, Zhang J, Quezada LLopez, Roberts J, Ling Y, Wood M, Shinwari W, Goullieux L, Roubert C, Fraisse L et al..  2022.  Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.. ACS Infect Dis. 8(3):557-573.
Gold B, Zhang J, Quezada LLopez, Roberts J, Ling Y, Wood M, Shinwari W, Goullieux L, Roubert C, Fraisse L et al..  2022.  Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.. ACS Infect Dis. 8(3):557-573.
Gold B, Zhang J, Quezada LLopez, Roberts J, Ling Y, Wood M, Shinwari W, Goullieux L, Roubert C, Fraisse L et al..  2022.  Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.. ACS Infect Dis. 8(3):557-573.
Lyu M, Suzuki H, Kang L, Gaspal F, Zhou W, Goc J, Zhou L, Zhou J, Zhang W, Shen Z et al..  2022.  ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut.. Nature. 610(7933):744-751.
Lyu M, Suzuki H, Kang L, Gaspal F, Zhou W, Goc J, Zhou L, Zhou J, Zhang W, Shen Z et al..  2022.  ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut.. Nature. 610(7933):744-751.
Lyu M, Suzuki H, Kang L, Gaspal F, Zhou W, Goc J, Zhou L, Zhou J, Zhang W, Shen Z et al..  2022.  ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut.. Nature. 610(7933):744-751.
Lyu M, Suzuki H, Kang L, Gaspal F, Zhou W, Goc J, Zhou L, Zhou J, Zhang W, Shen Z et al..  2022.  ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut.. Nature. 610(7933):744-751.
Ottavi S, Scarry SM, Mosior J, Ling Y, Roberts J, Singh A, Zhang D, Goullieux L, Roubert C, Bacqué E et al..  2022.  In Vitro and In Vivo Inhibition of the Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT by Amidinoureas.. J Med Chem. 65(3):1996-2022.
Ottavi S, Scarry SM, Mosior J, Ling Y, Roberts J, Singh A, Zhang D, Goullieux L, Roubert C, Bacqué E et al..  2022.  In Vitro and In Vivo Inhibition of the Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT by Amidinoureas.. J Med Chem. 65(3):1996-2022.
Ottavi S, Scarry SM, Mosior J, Ling Y, Roberts J, Singh A, Zhang D, Goullieux L, Roubert C, Bacqué E et al..  2022.  In Vitro and In Vivo Inhibition of the Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT by Amidinoureas.. J Med Chem. 65(3):1996-2022.
Green SR, Davis SH, Damerow S, Engelhart CA, Mathieson M, Baragaña B, Robinson DA, Tamjar J, Dawson A, Tamaki FK et al..  2022.  Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs.. Nat Commun. 13(1):5992.
Green SR, Davis SH, Damerow S, Engelhart CA, Mathieson M, Baragaña B, Robinson DA, Tamjar J, Dawson A, Tamaki FK et al..  2022.  Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs.. Nat Commun. 13(1):5992.
Green SR, Davis SH, Damerow S, Engelhart CA, Mathieson M, Baragaña B, Robinson DA, Tamjar J, Dawson A, Tamaki FK et al..  2022.  Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs.. Nat Commun. 13(1):5992.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al..  2022.  Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.. J Med Chem. 65(1):409-423.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al..  2022.  Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.. J Med Chem. 65(1):409-423.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al..  2022.  Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.. J Med Chem. 65(1):409-423.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al..  2022.  Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.. J Med Chem. 65(1):409-423.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al..  2022.  Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.. J Med Chem. 65(1):409-423.
Zhang L, Kent JE, Whitaker M, Young DC, Herrmann D, Aleshin AE, Ko Y-H, Cingolani G, Saad JS, D Moody B et al..  2022.  A periplasmic cinched protein is required for siderophore secretion and virulence of Mycobacterium tuberculosis.. Nat Commun. 13(1):2255.
Laurent P, Yang C, Rendeiro AF, Nilsson-Payant BE, Carrau L, Chandar V, Bram Y, tenOever BR, Elemento O, Ivashkiv LB et al..  2022.  Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19.. Sci Immunol. 7(75):eadd4906.
Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D et al..  2022.  Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.. J Med Chem. 65(9):6903-6925.
Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D et al..  2022.  Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.. J Med Chem. 65(9):6903-6925.